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Purpose: To investigate whether eyes with diabetic macular edema (DME) and central retinal 
thickness (CRT) .400 µm had better visual and anatomical outcomes compared to eyes with a 
CRT ,400 µm when treated with intravitreal bevacizumab in a real-world setting.
Patients and methods: Patients undergoing intravitreal bevacizumab therapy for DME were 
identified from the departmental database of a tertiary referral unit. Following the initial injec-
tion, a retreatment was performed for any persistent macular edema, unless there had been no 
previous response to repeated doses. Recorded parameters included visual acuity, CRT on optical 
coherence tomography (spectral domain optical coherence tomography [SD-OCT]), and SD-OCT 
characteristics. Comparisons were made between data at baseline and 12 months after the first 
injection, and differences were tested for statistical significance using the Student’s t-test.
Results: In all, 175 eyes of 142 patients were analyzed. Patients in group 2 (CRT .400 µm) 
had significantly more injections than group 1 (CRT ,400 µm) (4.0 versus 3.3; P=0.003). Both 
groups had similar numbers of eyes with preexisting epiretinal membrane and/or vitreomacular 
traction at baseline. The reduction in CRT was significantly greater in group 2 when compared 
to group 1 (P,0.0001). In terms of visual gain between baseline and month 12, each gained 
significantly by a mean of 0.12 logarithm of the minimum angle of resolution units (P=0.0001), 
but there was no difference between groups 1 and 2 (P=0.99).
Conclusion: These results do not support a 400 µm baseline CRT cut-off for treating DME 
with bevacizumab, in contrast to published data on ranibizumab. Our results also indicate that 
patients with a thicker CRT require more bevacizumab injections, making treatment less cost-
effective for these patients. Our results could be used by practitioners to support the use of 
bevacizumab in DME without applying a CRT cut-off.
Keywords: anti-VEGF therapy, central retinal thickness, ranibizumab, intravitreal injection, 
optical coherence tomography
Introduction
Diabetic macular edema (DME) is the leading cause of vision loss in patients with 
diabetes.1 Several studies have reported raised levels of vascular endothelial growth 
factor (VEGF) in the aqueous humor of eyes with DME when compared with healthy 
eyes.2–4 Anti-VEGF therapy with pegaptanib sodium, ranibizumab, bevacizumab, and 
aflibercept has been shown to have beneficial effects in terms of a reduction in edema 
and central retinal thickening as well as in terms of vision gain or stability.5–11
On February 27, 2013, the National Institute of Clinical Excellence in the UK 
recommended the use of ranibizumab for DME but only in the subgroup of patients 
with central retinal thickness (CRT) of .400 µm.12 This decision was based partly 
on the evidence from recent randomized clinical trials, which showed that eyes 
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with CRT .400 µm at baseline had more improvement in 
terms of visual acuity (VA) and CRT than those with CRT 
of ,400 µm.10,13
With regards to the bevacizumab therapy for DME, 
however, numerous studies have reported varying visual 
outcomes.8,14–16 Several studies have found that the pattern 
of edema classified on spectral domain optical coherence 
tomography (SD-OCT) has a significant influence on treat-
ment response and visual outcome.15–18
However, only one study to date has shown a greater 
treatment response to bevacizumab in eyes with a higher 
baseline CRT .350 µm.19 Given that the lower cost of small 
aliquots of bevacizumab from a compounding pharmacy has 
made bevacizumab a popular choice for intravitreal anti-
VEGF therapy in many countries,20 we therefore wanted to 
investigate whether eyes with DME and CRT .400 µm had 
better visual and anatomical outcomes when treated with 
bevacizumab in a real-world setting. This type of evidence 
may not only support the rationale of applying a CRT cut-off 
in treating DME with anti-VEGF therapy, but it may also be 
useful to clinicians in health care settings where patients have 
to opt for either ranibizumab or bevacizumab for personal 
economic reasons. In this study, we report visual and ana-
tomical outcomes of eyes with DME treated with intravitreal 
bevacizumab on a pro re nata basis at a single tertiary center, 
and we also compare visual outcomes at 1 year.
Materials and methods
The setting for this study was an intravitreal bevacizumab 
treatment service in a tertiary referral unit, provided by 
four specialists (PLL, SE, PS, BM) for patients with DME. 
Patients were referred from clinics within the Birmingham 
and Midland Eye Centre and from surrounding hospitals by 
their local ophthalmologists. Only the patients with center 
involving diffuse cystoid DME, or those that were unlikely 
to benefit from laser, were accepted into the treatment 
program.
Within the treatment program, eyes with DME were 
managed according to a standard treatment algorithm: 1) all 
patients had a baseline VA test, clinical examination, and SD-
OCT scan (Topcon 3D OCT 1000; TOPCON Corporation, 
Tokyo, Japan); 2) after written informed consent, patients 
received intravitreal bevacizumab (1.25 mg in 0.05 mL) under 
standard aseptic conditions (bevacizumab supplies were from 
Moorfields Eye Hospital’s compounding pharmacy); 3) fol-
lowing the first baseline treatment, patients attended one to 
three monthly monitoring visits for VA, biomicroscopy, and 
SD-OCT scan; 4) after the first injection, retreatment was 
 performed for any persistent macular edema on SD-OCT 
unless there had been no additional response observed after 
repeated dosing in previous visits; and 5) eyes that had mini-
mal or no response to intravitreal bevacizumab in terms of 
SD-OCT appearance were considered by the treating physi-
cian at any monitoring visit for intravitreal triamcinolone 
if this had not been tried prior to bevacizumab, as other 
intravitreal agents – such as ranibizumab, fluocinolone, and 
aflibercept – were not available at the time of the study.
From this treatment program, consecutive patients under-
going intravitreal bevacizumab therapy for DME in at least 
one eye were identified from the departmental database. To 
obtain an adequate sample size of patients with up to 1 year 
of follow-up, patients who had their first injection from March 
1, 2009–January 25, 2012, were included. Data capture was 
performed in March–April 2013 by means of retrospective 
chart review to obtain biographical, VA, and other data on 
injections and follow-up visits. The baseline was defined as 
the visit when the first intravitreal bevacizumab was admin-
istered. The final visit was defined as the visit that was either 
at 12 months from the baseline or the closest visit beyond 
the 12-month time point. Patients who had been discharged 
earlier than 12 months back to their local ophthalmologists 
in the surrounding hospital were excluded. Data on the 
number of intravitreal injections and the VA and the CRT at 
baseline and at the final 1-year time point were extracted from 
the charts and the SD-OCT database. In addition, baseline 
SD-OCT scans were retrospectively regraded to determine 
the presence of epiretinal membrane and vitreomacular 
traction, which are features known to be associated with a 
poor response.
To evaluate the differential treatment response of severe 
and less severe DME, patients were divided into group 1 
(,400 µm) and group 2 (.400 µm). Comparisons were 
made of CRT and VA between the groups and also within the 
groups (final versus baseline). Two sample, two-sided, unpaired 
Student’s t-tests were used to make comparisons between the 
two groups; one-sided, paired Student’s t-tests were used to 
compare the change in CRT and the VA within each group. 
Data analysis was performed using the Statistical Package 
for Social Sciences software (SPSS Inc., Chicago, IL, USA). 
P-values of ,0.05 were considered statistically significant.
Results
Data on 195 eyes of 159 patients were collected. Also, 20 eyes 
of 17 patients were excluded due to the following reasons: 
insufficient follow-up (eight eyes, six patients); lack of final 
SD-OCT (four eyes, four patients); delay in 12-month review 
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date by more than 2 months (three eyes, two patients); coex-
isting retinal vein occlusion (two eyes, two patients); and 
missing data on acuity or treatment dates (three eyes, three 
patients). A total of 175 eyes of 142 patients were included in 
analysis. All eyes were confirmed on retrospective SD-OCT 
regrading to have a cystoid pattern of DME with cysts in 
either inner or outer retinal layers.
Of these, 81 eyes of 66 patients had CRT ,400 µm 
(group 1) and 94 eyes of 76 patients had CRT .400 µm 
(group 2). The baseline characteristics of these two groups 
of eyes and their exposure to treatment over the 12-month 
period are shown in Table 1. Both groups had similar num-
bers of eyes with preexisting epiretinal membrane and/or 
vitreomacular traction visible on SD-OCT at the baseline. 
Although very few patients required intravitreal triamci-
nolone during the study period, more patients in group 2 
required it. Four patients in group 1 received intravitreal 
triamcinolone compared to eight in group 2 during the study 
period. Group 2 patients had significantly more injections 
than group 1 patients (4.0 versus 3.3; P=0.003). The results 
for CRT are shown in Table 2. Both groups showed a signifi-
cant reduction in CRT between the baseline and month 12. 
The amount of reduction in CRT was significantly greater in 
group 2 when compared to group 1 (P,0.0001).
In terms of VA, both groups had comparable visual acu-
ities at the baseline and gained by a mean of 0.12 logarithm of 
the minimum angle of resolution (logMAR) units (equivalent 
to six letters) between baseline and month 12. The difference 
between groups 1 and 2 in terms of visual gain was not sta-
tistically significant (P=0.99). Within each group, however, 
there was an improvement in the VA from the baseline to the 
final of 0.12 logMAR units. This was statistically significant 
(P=0.0001). The VA results are shown in Table 3.
Discussion
The results from this study demonstrated the treatment 
response that could be achieved with intravitreal bevacizumab, 
as both groups of eyes showed a significant improvement in 
CRT measurements, with the greatest anatomical response in 
the group with CRT .400 µm. This finding of a differential 
anatomical response depending on baseline CRT is in keeping 
with one study using bevacizumab by Soheilian et al and also 
in studies using ranibizumab.13,19,21 Evidence for a differential 
response in terms of visual gain is less clear. In this study, 
Table 1 Distribution of patients, eyes, and treatment in 
groups 1 and 2
Parameter Group 1  
(,400 μm)
Group 2 
(.400 μm)
number of patients (% female) 66 (46%) 76 (33%)
Mean age in years (range) 63 (19–87) 63 (27–87)
Mean age – group comparison  
(unpaired student’s t-test)
P=0.34
number of bilaterally treated  
patients
15 18
Total number of eyes 81 eyes 94 eyes
eyes with erM or VMT at baseline 16/83 (19.3%) 23/94 (24.5%)
Mean number of injections:  
(mode, range, total)
3.3 (3, 1–8, 272) 4.0 (3, 1–9, 375)
number of injections – group  
comparison (unpaired student’s t-test)
P=0.003
Abbreviations: erM, epiretinal membrane; VMT, vitreomacular traction.
Table 3 Va at baseline and at 12 months in groups 1 and 2
Group 1  
(,400 μm)
Group 2  
(.400 μm)
Mean baseline acuity – logMar  
units (sD, range)
0.58 (≈20/80) 
(0.31, 0.18–1.50)
0.67 (≈20/100) 
(0.35, 0.18–1.78)
Mean baseline acuity – difference 
between groups (unpaired  
student’s t-test)
0.09, P=0.06
Mean final acuity in logMAR  
units (sD, range) 
0.45 (≈20/63) 
(0.29, 0.00–1.3)
0.55 (≈20/80) 
(0.33, 0.00–1.78)
Mean final acuity – difference  
between groups (unpaired  
student’s t-test)
0.10, P=0.049
Mean gain in Va within group  
(sD, range) (minus denotes visual 
loss) (paired student’s t-test)
+0.12 (0.28,  
-0.52 to +1.20) 
P=0.0001
+0.12 (0.28, 
-0.78 to +1.00) 
P,0.0001
Mean gain in Va – difference 
between groups (unpaired 
student’s t-test)
0.00, P=0.99
Abbreviations: Va, visual acuity; logMar, logarithm of the minimum angle of 
resolution; sD, standard deviation.
Table 2 CrT at baseline and 12 months in groups 1 and 2
Group 1  
(,400 μm)
Group 2  
(.400 μm)
Mean baseline CrT in µm  
(sD, range)
326 (43.8, 232–395) 539 (106.3, 402–846)
group difference  
(unpaired student’s t-test)
213; P,0.0001; (P=6.2 × 10-39)
Mean final CRT in µm  
(sD, range)
293 (69.3, 134–475) 393 (128.5, 166–776)
group difference  
(unpaired student’s t-test)
100, P,0.0001
Mean reduction in  
CrT in µm (sD, range)  
(minus denotes worsening)  
(paired student’s t-test)
33.6, (75.6; -185  
to +220) P=0.0001
146, (132.8; -211  
to +570) P,0.0001
Mean between group  
reduction in CrT in µm  
(unpaired student’s t-test)
112.4; P,0.0001
Abbreviations: CrT, central retinal thickness; sD, standard deviation.
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we could not demonstrate a significant difference in visual 
outcome between eyes with .400 µm or ,400 µm of CRT 
due to DME but admittedly the entry criteria of this study 
differed from the ranibizumab clinical trials in that the mean 
baseline VA in our study was lower by about 0.2 logMAR 
units (ten letters). Both groups had a modest improvement 
of about six letters (1.2 logMAR units).
To our knowledge, only one published study on bevaci-
zumab in DME has performed subgroup analysis of visual 
outcome based on baseline CRT.19 In that study,  Soheilian 
et al19 found that eyes with a baseline central macular thickness 
of ,250 µm had significantly greater VA improvement than 
eyes with .350 µm but their follow-up period was only up 
to 36 weeks. It is also worthwhile to note that a reduction on 
foveal thickness has also been demonstrated in a study that 
used intravitreal pegaptanib.22
These results suggest that in terms of differential visual 
gain from treating DME with bevacizumab, the 350 µm or 
400 µm baseline CRT cut-off is not currently supported 
by the evidence from this study and from the published 
literature. This is in contrast to the published data on ranibi-
zumab in DME. In the RESTORE study, for instance, eyes 
with a baseline CRT of .400 µm gained approximately 
six letters while the eyes with a baseline CRT of ,300 µm 
gained only three letters at 12 months.10 In the Diabetic 
Retinopathy Clinical Research Network Protocol I study, 
eyes with a baseline CRT of .400 µm had a mean gain of 
eleven letters while eyes with ,400 µm had a mean gain of 
seven letters at 2 years.13
A possible reason for the discrepancy in differential visual 
outcome between our study and those from large clinical tri-
als could be due to the chronicity of DME. In our study, all 
patients had cystoid pattern on regrading of SD-OCT; this 
would indicate a population with more chronic DME. In the 
Diabetic Retinopathy Clinical Research Network Protocol 
I study, approximately 40% of all patients treated with 
ranibizumab did not have prior laser and, in the RESTORE 
study, the mean duration of DME prior to study entry was 
,2 years.10,13 Indeed, the chronicity of DME and the presence 
of cystoid spaces on SD-OCT were found by Shimura et al 
to be poor prognostic factors for visual improvement when 
treated with intravitreal bevacizumab.18
In this study, both groups had a small or modest gain 
in VA, despite achieving a considerable reduction in CRT. 
This may be explained by a poor correlation between the 
functional and the anatomical response, which has been 
described with bevacizumab and between triamcinolone 
and ranibizumab.13,21,23 The other explanation is the lack 
of correlation between CRT and VA, which is also well 
documented.24–26 The lack of correlation between macular 
thickness and VA suggests that an anatomical parameter, 
based on a finite threshold of macular thickness, is unlikely 
to be a good predictor of treatment response in terms of 
visual gain.
We also found that patients in group 2 received more 
injections than group 1. This would have the effect of making 
the treatment less cost-effective in patients with thicker CRT. 
The differential number of injections between subgroups 
in the RESTORE and protocol I studies was not taken into 
account when the cost-effectiveness of each subgroup was 
considered in the National Institute of Clinical Excellence 
appraisal of ranibizumab for DME.10,12,13 This may have led 
to an overestimation of the cost-effectiveness of treating the 
subgroup of patients with DME .400 µm.
This retrospective case series has several limitations. 
Visual acuities were not measured with a refraction protocol 
at regular visits as in a prospective clinical trial. Criteria for 
Group 1 (<400 µm)
Group 2 (>400 µm)
CR
T 
in
 µ
m
Figure 1 Comparison of initial and final CRT between groups 1 and 2.
Notes: Standard error bars are included. Both groups showed a significant reduction 
in CRT between the baseline and month 12, with a significantly greater reduction in 
group 2 compared to group 1.
Abbreviation: CrT, central retinal thickness.
Group 1 (<400 µm)
Group 2 (>400 µm)
VA
 in
 lo
gM
AR
 u
ni
ts
Figure 2 Comparison of initial and final VA between group 1 and group 2.
Notes: standard error bars are included. Both groups gained by a mean of 
0.12 logMar units between baseline and month 12. There was no statistical 
difference between groups 1 and 2 in terms of vision gain.
Abbreviations: Va, visual acuity; logMar, logarithm of the minimum angle of 
resolution.
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retreatment could have been variable throughout the study. 
Therefore, the overall efficacy of bevacizumab therapy could 
not be judged from our visual outcome data. However, this 
is unlikely to have a great impact on the interpretation of 
the difference in treatment response between eyes with 
.400 µm or ,400 µm of DME, as we performed SD-OCT 
regrading to ensure that both groups were balanced in terms 
of consistency of CRT measurements, presence of cystoid 
change, and confounding characteristics, such as epiretinal 
membrane. We were able to balance the two groups in terms 
of influencing factors, such as epiretinal membrane pres-
ence, sex, and age, but we did not have the ability to collect 
accurate data to demonstrate the balance of other influential 
factors such as the duration of diabetes and blood pressure. 
As the patients in this study were all at the severe end of the 
spectrum, we feel it is unlikely that this omission should affect 
our ability to answer the specific study question on the issue 
of a 400 µm threshold. A final limitation was the absence of 
a ranibizumab control. Findings from bevacizumab-treated 
eyes may not translate to a ranibizumab scenario. The absence 
of an effect of a 400 µm threshold seen in this study does 
not necessarily invalidate the 400 µm threshold seen in the 
ranibizumab studies, such as the RESTORE trial.
The strength of this study lies in the consecutive nature 
of its fairly large series, which we feel reflects the unselected 
population that would present to any secondary care facil-
ity providing bevacizumab therapy for patients with DME. 
Therefore, our study results should be useful for practitioners 
who have to consider the use of bevacizumab in patients with 
CRT of either .400 µm or ,400 µm without applying other 
exclusion criteria, such as DME duration, blood pressure, 
glycemic control, or SD-OCT pattern – as would be the case 
when translating from prospective randomized trials designed 
to evaluate efficacy. The issue of the unlicensed use of beva-
cizumab for the treatment of DME, when there is a licensed 
alternative (ranibizumab), is still a controversial one.
A recent review27 of published outcomes on the use of 
these two agents in various studies for this indication did not 
reveal any significant differences in clinical effectiveness and 
adverse events, and we agree with the authors of this review 
that a head-to-head study would provide a much-needed 
evidence base for those clinicians who have to continue using 
bevacizumab for treatment of DME.
Conclusion
In conclusion, we were unable to demonstrate a differ-
ence in functional outcome between patients who were 
grouped according to an anatomical threshold of 400 µm of 
CRT at baseline. Our results do not support a preferential 
selection of those with DME and CRT .400 µm at the baseline 
for intravitreal bevacizumab. On the contrary, we found that 
patients with thicker CRT required more injections rendering 
the treatment potentially less cost-effective. As there are no 
published studies to show equivalence between bevacizumab 
and ranibizumab for DME, it is not possible to say if we can 
translate these findings in the use of ranibizumab in DME.
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